First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial

First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial
The first ovarian cancer patient in the APOLLO Phase 1 clinical trial has been dosed with FATE-NK100, Fate Therapeutics' investigational NK (natural killer) cell therapy. The Phase 1 trial (NCT03213964), which is currently recruiting participants, was designed to determine the maximum dose of a single FATE-NK100 infusion — the primary endpoint — in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. The treatment is administered via an intraperitoneal catheter (a soft tube inserted into the abdomen) in patients who received prior platinum-based chemotherapy and are either platinum-resistant or platinum-sensitive. Within 30 minutes of the FATE-NK100 infusion, patients receive a subcutaneous interleukin-2 (IL-2) injection at the medical center. The remaining IL-2 doses are given in an outpatient setting, three times a week for a total of six doses. IL-2 is the only U.S. Food and Drug Administration (FDA)-approved therapy that promotes NK cell activation and survival. The therapy is sold under different brand names, including Proleukin and Aldesleukin. Researchers will assess the safety of three different doses of FATE-NK100 — 10 million cells per kg body weight, between 10 and 30 million cells per kg, and up to 100 million cells per kg. Secondary endpoints include objective response rate at 28 days, and progression-free and overall survival at six months after the FATE-NK100 infusion. FATE-NK100 is an investigational cancer immunotherapy composed of donor-derived NK cells — key cells of the innate immune system — that have been activated in the lab for enhanced anti-tumor activity. The therapy uses a particular subset of NK that show a maturation marker called CD57. In preclinical studies, FATE-NK100 showed broa
Subscribe or to access all post and page content.